Long-Term Treatment With Cimetidine in Duodenal Ulceration

Bardhan, Karna Dev; Blum, A. L.; Gillespie, G; Larkworthy, William; Mekel, R. C. P. M.; Moshal, M G; Smith, Paul M.; Venables, C W; Tongeren, J. H. M. Van; Walan, A

doi:10.1016/s0140-6736(77)91219-3

Cited by 24 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The finding that 4 of the 21 patients failed to achieve healing of their ulcers on a month's course of cimetidine confirms the work of Bardhan (5). The high relapse rate occurring in 9 of the remaining 17 patients (53 per cent) is similar to the 42 per cent with recurrence of symptoms in a placebo-treated group reported by Bardhan 4) found a higher incidence of ulcer relapse when endoscopic examination was used than when symptoms alone were considered.…”

Section: Discussionsupporting

confidence: 70%

The value of the new interpretation of the insulin test in predicting duodenal ulcer relapse after treatment with cimetidine

Maybury

Carr‐Locke

1980

Journal of British Surgery

View full text Add to dashboard Cite

Twenty-one patients with duodenal ulcer were treated with cimetidine. After 2 weeks they were submitted to an insulin test and the results were compared with a range of secretion previously established in untreated duodenal ulcer patients (1). The secretion of 13 patients fell within this range and so they were predicted to have a high risk of relapse. The patients whose secretion was below the range had a predicted low risk of relapse. After 4 weeks' treatment repeat endoscopy showed that 4 ulcers had failed to heal. The secretion of 3 of the patients was within the range of the high risk group. The remaining 17 patients were followed up (range 20-23 months): 9 relapsed and 8 remained symptom-free. Eight of the 9 were in the high risk group and 6 of the 8 symptom-free patients were in the low risk group. In all, 11 out of 13 were correctly predicted in the high risk group and 6 out of 8 in the low risk group. The performance of the insulin test in predicting liability to relapse following cimetidine treatment was significant (P = 0.0225).

show abstract

Section: Discussionsupporting

confidence: 70%

The value of the new interpretation of the insulin test in predicting duodenal ulcer relapse after treatment with cimetidine

Maybury

Carr‐Locke

1980

Journal of British Surgery

View full text Add to dashboard Cite

show abstract

“…However, as conventional H2 receptor antagonists, such as cimetidine, achieve ulcer healing in 80% of patients at the very most (Bardhan, 1978) and furthermore may produce adverse (Kruss & Littman, 1978;Lavarenne & Moreau, 1980), the search for more selective and less toxic H2 receptor antagonists remains mandatory.…”

Section: Introductionmentioning

confidence: 99%

Ranitidine upon meal‐induced gastric secretion: oral pharmacokinetics and plasma concentration effect relationships.

Mignon¹,

Chau²,

Bk³

et al. 1982

Brit J Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…A further 13 patients meeting our criteria were studied over two separate 24 hour periods receiving either no treatment or 1211 Gledhill, Buck, and Hunt cimetidine 1 g/day.…”

Section: Pati Entsmentioning

confidence: 99%

Effect of no treatment, cimetidine 1 g/day, cimetidine 2 g/day and cimetidine combined with atropine on nocturnal gastric secretion in cimetidine non-responders.

Gledhill¹,

Buck²,

Hunt³

1984

Gut

View full text Add to dashboard Cite

SUMMARY We have studied nocturnal acid secretion in patients with duodenal ulcer who met predetermined criteria of poor clinical response to cimetidine. Different groups of patients were investigated receiving either no treatment, cimetidine 1 g/day, cimetidine 2 g/day or cimetidine 1 g/day combined with atropine 4.8 mg/day. In the present study we have taken a group of patients who prospectively met criteria of poor response to cimetidine (non-responders) and compared the overnight hydrogen ion activity and acid output with that obtained from unselected duodenal ulcer patients studied previously in our department but who were not classified as being a responder or non-responder. We also studied the

show abstract

Long-Term Treatment With Cimetidine in Duodenal Ulceration

Cited by 24 publications

References 0 publications

The value of the new interpretation of the insulin test in predicting duodenal ulcer relapse after treatment with cimetidine

The value of the new interpretation of the insulin test in predicting duodenal ulcer relapse after treatment with cimetidine

Ranitidine upon meal‐induced gastric secretion: oral pharmacokinetics and plasma concentration effect relationships.

Effect of no treatment, cimetidine 1 g/day, cimetidine 2 g/day and cimetidine combined with atropine on nocturnal gastric secretion in cimetidine non-responders.

Contact Info

Product

Resources

About